Skip to main content Accessibility help
×
Home
Hostname: page-component-768ffcd9cc-6vg6l Total loading time: 1.183 Render date: 2022-11-30T13:04:02.850Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "displayNetworkTab": true, "displayNetworkMapGraph": false, "useSa": true } hasContentIssue true

Tobacco smoking as a risk factor for major depressive disorder: population-based study

Published online by Cambridge University Press:  02 January 2018

Julie A. Pasco*
Affiliation:
Department of Clinical and Biomedical Science: Barwon Health, The University of Melbourne, Victoria
Lana J. Williams
Affiliation:
Department of Clinical and Biomedical Science: Barwon Health, The University of Melbourne, Victoria
Felice N. Jacka
Affiliation:
Department of Clinical and Biomedical Science: Barwon Health, The University of Melbourne, Victoria
Felicity Ng
Affiliation:
Department of Clinical and Biomedical Science: Barwon Health, The University of Melbourne, Victoria
Margaret J. Henry
Affiliation:
Department of Clinical and Biomedical Science: Barwon Health, The University of Melbourne, Victoria
Geoffrey C. Nicholson
Affiliation:
Department of Clinical and Biomedical Science: Barwon Health, The University of Melbourne, Victoria
Mark A. Kotowicz
Affiliation:
Department of Clinical and Biomedical Science: Barwon Health, The University of Melbourne, Victoria
Michael Berk
Affiliation:
Department of Clinical and Biomedical Science: Barwon Health, The University of Melbourne, Victoria, and Orygen Research Centre and Mental Health Research Institute, Australia
*
Julie A. Pasco, Epidemiology and Biostatistics Unit, Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, PO Box 281, Geelong 3220, Australia. Email: juliep@barwonhealth.org.au
Rights & Permissions[Opens in a new window]

Abstract

Background

Smoking is disproportionately prevalent among people with psychiatric illness.

Aims

To investigate smoking as a risk factor for major depressive disorder.

Method

A population-based sample of women was studied using case–control and retrospective cohort study designs. Exposure to smoking was self-reported, and major depressive disorder diagnosed using the Structured Clinical Interview for DSM–IV–TR (SCID–I/NP).

Results

Among 165 people with major depressive disorder and 806 controls, smoking was associated with increased odds for major depressive disorder (age-adjusted odds ratio (OR)=1.46, 95% CI 1.03–2.07). Compared with non-smokers, odds for major depressive disorder more than doubled for heavy smokers (>20 cigarettes/day). Among 671 women with no history of major depressive disorder at baseline, 13 of 87 smokers and 38 of 584 non-smokers developed de novo major depressive disorder during a decade of follow-up. Smoking increased major depressive disorder risk by 93% (hazard ratio (HR)=1.93, 95% CI 1.02–3.69); this was not explained by physical activity or alcohol consumption.

Conclusions

Evidence from cross-sectional and longitudinal data suggests that smoking increases the risk of major depressive disorder in women.

Type
Papers
Copyright
Copyright © Royal College of Psychiatrists, 2008 

Tobacco smoking is a major public health problem and several preventive public health strategies have been implemented. However, smoking remains disproportionately prevalent among people with psychiatric illness Reference Grant, Hasin, Chou, Stinson and Dawson1,Reference Kilian, Becker, Kruger, Schmid and Frasch2 and this is often considered within the mental health profession to be a secondary or deferrable treatment goal to the control of the psychiatric illness. It is becoming increasingly clear that smoking is not innocuous to mental health, and may in fact aggravate mental illness or contribute to its onset. On a neurobiological level, this may be related to the impact of nicotine on monoamine neurotransmitter regulation, including dopamine, via the diffuse cholinergic pathways. Reference Dani and De Biasi3 This may underlie the circadian dysrhythmicity and hedonic dysregulation in smokers, Reference Adan, Prat and Sanchez-Turet4 and may predispose to the development of mood disorders. Smoking also has other systemic and metabolic consequences that may likewise increase this vulnerability.

There is already evidence that smoking is a risk factor for depression. Association data from cross-sectional studies Reference Harlow, Cohen, Otto, Spiegelman and Cramer5,Reference Hamalainen, Kaprio, Isometsa, Heikkinen, Poikolainen, Lindeman and Aro6 support evidence from prospective studies to suggest that smoking pre-dates the onset of depression. Reference Klungsoyr, Nygard, Sorensen and Sandanger7,Reference Steuber and Danner8 However, there is only limited longitudinal data in the existing literature, and most longitudinal studies have involved time frames under 2 years, which may not be adequate to demonstrate the insidious effects of nicotine dependence. In this epidemiological study, we investigated the status of tobacco smoking as a risk factor for major depression using not only cross-sectional data but also longitudinal data that extend over a period of 10 years.

Method

Participants

This study is nested within the Geelong Osteoporosis Study, a programme of research originally designed to investigate the epidemiology of osteoporosis in Australian women, but recently expanded to examine both psychiatric illness and non-psychiatric diseases. The criterion for inclusion into the Geelong Osteoporosis Study is women listed on the current Australian Commonwealth electoral roll for the region known as the Barwon Statistical Division and the criteria for exclusion are inability to provide informed consent, death, and not able to be contacted. Reasons for non-participation are described elsewhere. Reference Henry, Pasco, Nicholson, Seeman and Kotowicz9 During the period 1994–1997, 1494 women recruited into the Geelong Osteoporosis Study have been prospectively followed for a decade. At the time of writing, a further 208 had been recruited during 2005–2007. A total of 1043 women (aged 20–93 years) participated in a psychiatric assessment during the period 2004–2007, thus fulfilling the inclusion criteria for this study. The Barwon Health Research and Ethics Advisory Committee approved the study, and all participants provided informed, written consent.

Data

Lifestyle practices including smoking, alcohol consumption, habitual physical activity levels and exposure to disease were self-reported. Smoking was recognised if individuals reported regularly smoking more than one or two cigarettes per day for at least 6 months, and recorded details of smoking included frequency and period of exposure. Alcohol intake was recognised if alcohol was consumed several times per week or every day. Habitual physical activity was classified as active if participants reported ‘moving, walking and working energetically and participating in vigorous exercise’, otherwise they were classified as sedentary. Cardiovascular disease included hypertension, angina and coronary artery disease; diabetes encompassed both types 1 and 2. Socio-economic status was ascertained using Socio-Economic Index for Areas index scores based on census data from the Australian Bureau of Statistics. Reference Adhikari10 These data were used to derive an Index of Economic Resources (IER), which was categorised into five groups, according to quintiles of IER for the study region.

The Structured Clinical Interview for DSM–IV–TR Research Version, Non-patient Edition (SCID–I/NP) Reference First, Spitzer, Gibbon and Williams11 was used to identify women with a lifetime history of major depressive disorder and to determine age at onset. Psychiatric interviews were conducted by trained personnel.

Study designs

Case–control

Among 1043 women who underwent psychiatric assessment, 237 were diagnosed with major depressive disorder and 806 had no history of major depressive disorder. Exposure to smoking was recognised if smoking was practised prior to the onset of major depression. Sixty-eight individuals were excluded because their age at major depressive disorder onset was less than 20 years (the minimum age for controls) and four were excluded because it was unclear whether smoking pre- or post-dated major depressive disorder onset. Thus, 165 individuals with major depressive disorder and 806 controls were eligible for analysis in this case–control study.

Retrospective cohort

Among 1043 women who underwent psychiatric assessment, a decade of longitudinal data was available for 835. Based on retrospective data, 164 were excluded because they had experienced a major depressive disorder episode prior to baseline. Among the 671 women aged 20–84 years with no history of major depressive disorder at baseline and who were thus eligible for analysis in this retrospective cohort study, 51 developed de novo major depressive disorder and 620 remained major depressive disorder-free during follow-up. Participants were classified as smokers if they were current smokers at baseline, otherwise they were classified as non-smokers.

Statistics

Statistical analyses were performed using Stata (version 9.0) and Minitab (version 13). Standard descriptive statistics were used to characterise the participants in each study.

In the case–control study, participants were selected as cases (people with major depressive disorder) or controls (people with no major depressive disorder), and exposure to smoking was documented for each group. Logistic regression modelling was performed to determine the association between smoking and major depressive disorder. Age was defined as the age at major depressive disorder onset for cases and age at baseline for controls, and was categorised into age groups for analysis. Smoking was investigated as a binary variable and was also categorised into groups according to the average number of cigarettes smoked per day (0, ⩽10, 11–20, >20 cigarettes/day). Age, socio-economic status, physical illness, physical activity and alcohol consumption were tested in the models as potential confounders and effect modifiers.

In the cohort study, participants with no history of major depressive disorder at baseline were selected, categorised as current smokers or not, and followed until a first major depressive disorder episode or until the end of the follow-up period. The effect of smoking on development of de novo major depressive disorder was examined using multivariate Cox proportional hazards regression analysis, using age as the time axis. The proportional hazards assumptions were checked using Schoenfeld residuals before and after adjusting for potential confounding by socio-economic status, physical illness, physical activity and alcohol consumption.

Results

Case–control study

Characteristics of the participants involved in the case–control analysis are shown in Table 1. Participants with major depressive disorder were younger and were more often smokers. Exposure to smoking was documented for 73 of the 165 people with major depressive disorder and for 269 of 806 controls. Prevalence of smoking was thus greater among women with major depressive disorder (0.44 (95% CI 0.37–0.52) v. 0.33 (95% CI 0.30–0.37), P=0.008). Exposure to smoking increased the odds for major depressive disorder (odds ratio OR=1.58, 95% CI 1.13–2.23, P=0.008) and this association persisted, albeit attenuated, after adjusting for age (age-adjusted OR=1.46, 95% CI 1.03–2.07, P=0.031). Socio-economic status did not confound the association between smoking and major depressive disorder (age- and socio-economic status-adjusted OR=1.49, 95% CI 1.05–2.11, P=0.026). Similarly, the association was not explained by a history of self-reported cardiovascular disease or diabetes (adjusted OR=1.47, 95% CI 1.04–2.09, P=0.030). Among the 342 smokers, participants with major depressive disorder smoked more heavily than those in the control group (median (interquartile range), 15 (10–20) v. 10 (8–20) cigarettes per day, P=0.059). Compared with non-smokers, the odds for major depressive disorder tended to increase 1.47-fold for women who smoked 11–20 cigarettes per day (P=0.094) and more than doubled for those who smoked more than 20 cigarettes per day (P=0.003) (Table 2).

Table 1 Participant characteristics in the case–control study

Major depressive disorder (n=165) No major depressive disorder (n=806) P
Age, years: median (IQR) 33 (26–45) 43 (29–59) <0.0001
Smokers, n (%) 73 (44) 269 (33) 0.008
Socio-economic status, n (%) 0.857
   Quintile 1 (low) 23 (14) 125 (16)
   Quintile 2 33 (20) 184 (23)
   Quintile 3 41 (25) 183 (23)
   Quintile 4 29 (18) 142 (18)
   Quintile 5 39 (24) 172 (21)
Alcohol users, n (%) 28 (17) 144 (18) 0.784
Physically active, n (%) 31 (19) 168 (21) 0.551
Cardiovascular disease, n (%) 56 (34) 240 (30) 0.290
Diabetes, n (%) 11 (7) 48 (6) 0.727

IQR, interquartile range

Table 2 Smoking frequency (number of cigarettes per day) and the risk for major depression a

Cigarettes per day Unadjusted OR (95% CI) Age-adjusted OR (95% CI)
<10 1.02 (0.56–1.88) 0.88 (0.48–1.64)
11–20 1.62 (1.04–2.52) 1.47 (0.94–2.32)
>20 2.17 (1.31–3.58) 2.18 (1.31–3.65)

a. Non-smokers form the reference group

Being physically active was found to be protective against major depressive disorder (age-adjusted OR=0.58, 95% CI 0.37–0.91, P=0.017). None the less, the association between smoking and major depressive disorder was not explained by differences in physical activity. The independent relationships between smoking and physical activity on the risk for major depressive disorder are shown in Fig. 1. Alcohol consumption did not affect this association.

Fig. 1 Independent contributions of tobacco smoking and physical activity to the risk for major depression. Non-smokers who are physically active form the reference group.

Retrospective cohort study

Characteristics of women included in this analysis are shown in Table 3. Among 87 women who were current smokers at baseline, 13 developed de novo major depressive disorder during 781 person-years of observation, whereas among 584 non-smokers, 38 developed major depressive disorder during 5384 person-years of observation. Estimated rates of major depressive disorder were 16.6 (95% CI 9.7–28.7) per 1000 person-years for smokers and 7.1 (95% CI 5.1–9.7) per 1000 person-years for non-smokers.

Table 3 Participant characteristics in the retrospective cohort study

Smokers (n=87) Non-smokers (n=584) P
Age, years: median (IQR) 39 (31–52) 50 (37–63) <0.0001
Major depressive disorder, n (%) 13 (15) 38 (7) 0.006
Socio-economic status, n (%) 0.001
   Quintile 1 (low) 26 (30) 93 (16)
   Quintile 2 19 (22) 137 (23)
   Quintile 3 22 (25) 107 (18)
   Quintile 4 6 (7) 114 (20)
   Quintile 5 14 (16) 133 (23)
Alcohol users, n (%) 20 (23) 96 (16) 0.132
Physically active, n (%) 14 (16) 69 (12) 0.258
Cardiovascular disease, n (%) 20 (23) 220 (38) 0.006
Diabetes, n (%) 3 (3) 44 (8) 0.129

IQR, interquartile range

Exposure to smoking was found to increase the risk for developing a first episode of major depressive disorder by 93%, hazard ratio (HR)=1.93 (95% CI 1.02–3.69, P=0.045). A Kaplan–Meier survival plot showing the probability of remaining free of major depressive disorder over a 10-year period for women exposed and unexposed to smoking at baseline is shown in Fig. 2. Adjustment for socio-economic status enhanced the risk (adjusted HR= 2.01, 95% CI 1.03–3.93, P=0.042). Further adjustment for alcohol consumption, physical activity or physical illness did not attenuate this association.

Fig. 2 Survival plot (Kaplan–Meier) showing the probability of remaining free of de novo major depressive disorder over a 10-year period for smokers and non-smokers at baseline.

Discussion

This study provides both cross-sectional and longitudinal evidence consistent with the hypothesis that tobacco smoking is associated with major depression. Our cross-sectional data demonstrate that exposure to smoking is associated with a 1.46-fold increase in the odds for major depressive disorder. Furthermore, our findings are suggestive of a dose-dependent association, with more than a two-fold increase in the odds of major depressive disorder for heavy smokers compared with non-smokers. With the advantage of temporal sequencing, our longitudinal data demonstrate that smoking is associated with a near doubling of risk for developing de novo major depressive disorder over a 10-year period. These effects were independent of age and physical activity, and not explained by alcohol consumption.

Other cross-sectional studies have reported increased odds of depression in smokers, Reference Harlow, Cohen, Otto, Spiegelman and Cramer5,Reference Hamalainen, Kaprio, Isometsa, Heikkinen, Poikolainen, Lindeman and Aro6 with results retaining statistical significance after adjusting for other major risk factors. Reference Hamalainen, Kaprio, Isometsa, Heikkinen, Poikolainen, Lindeman and Aro6 Prospective studies, although limited, have further strengthened the suspected role of smoking in depression. In an 11-year population-based longitudinal Norwegian study, the hazard ratio for a first depressive episode increased with smoking in a dose-dependent fashion, such that the heaviest smokers (exceeding 20 cigarettes per day) had over four times the risk of those who had never smoked. Reference Klungsoyr, Nygard, Sorensen and Sandanger7 Increased incidence of major depression in smokers has been reported in other shorter studies, Reference Breslau, Kilbey and Andreski12,Reference Breslau, Peterson, Schultz, Chilcoat and Andreski13 including data from adolescents. Reference Brown, Lewinsohn, Seeley and Wagner14 Longitudinal studies have also shown a reverse relationship, in which the presence of depression increased the risk of smoking progression. Reference Breslau, Kilbey and Andreski12,Reference Breslau, Peterson, Schultz, Chilcoat and Andreski13 Positive effects on psychomotor performance and enhanced craving, as demonstrated in a physiological study, Reference Malpass and Higgs15 may be pertinent factors for this observation. Other studies have provided support for a third possibility, that depression and smoking coexist as epiphenomena of a common underlying cause, such as genetic factors. Reference Kendler, Neale, MacLean, Heath, Eaves and Kessler16,Reference Korhonen, Broms, Varjonen, Romanov, Koskenvuo, Kinnunen and Kaprio17 The efficacy of bupropion in the treatment of both depression and nicotine dependence Reference Foley, DeSanty and Kast18 may indicate some commonality between the two conditions on a neurochemical level.

Dopamine is one such factor, which is believed to have a dual role in depression and in the mechanism of addiction. Neurochemical studies of depression, particularly with psychomotor retardation, reported an association with diminished dopamine metabolism, as evidenced by decreased levels of cerebrospinal fluid homovanillic acid. Reference Korf and van Praag19,Reference Post, Kotin, Goodwin and Gordon20 Reduced striatal dopamine function has also been shown in dopamine D2 receptor neuroimaging binding studies. Reference Ebert, Feistel, Loew and Pirner21,Reference Martinot, Bragulat, Artiges, Dolle, Hinnen, Jouvent and Martinot22 Dopamine is regarded as the central neurotransmitter of reward, and as having a key role in the reinforcement of the pathways to addiction. Reference Di Chiara and Bassareo23 Dysregulation of the dopaminergic system in addictive states is also a plausible mechanistic pathway to depressive vulnerability. Reference Malhi and Berk24

Smoking-induced oxidative stress is another factor. Tobacco smoke generates free radicals, causing lipid peroxidation, oxidation of proteins and other tissue damage in smokers. Reference Hulea, Olinescu, Nita, Crocnan and Kummerow25,Reference Ozguner, Koyu and Cesur26 Depression has been characterised by elevated markers of oxidative stress Reference Ozcan, Gulec, Ozerol, Polat and Akyol27Reference Khanzode, Dakhale, Khanzode, Saoji and Palasodkar29 that demonstrates a positive correlation with depressive severity Reference Yanik, Erel and Katoi30 and a return to normal levels after treatment. Reference Bilici, Efe, Koroglu, Uydu, Bekaroglu and Deger28,Reference Khanzode, Dakhale, Khanzode, Saoji and Palasodkar29 It seems plausible that depression could be among the oxidative stress sequelae of smoking.

There are several strengths and potential weaknesses in our study. The length of the follow-up period is a key strength, especially when published longitudinal studies have rarely exceeded a few years at most. Given that smoking effects insidious biochemical changes that are naturally accommodated by the body's homeostatic responses, long-term sequelae such as depression, cancers, cardiovascular and pulmonary diseases may only be reliably demonstrated over an extended time frame. Recall limitations may have affected our ability to accurately diagnose the time of onset of depressive episodes and, in the case–control analysis, the potential exists for differential recall bias of smoking practices. However, as this study was nested within a larger prospective study, the latter risk was minimised as exposure to smoking had been documented prior to psychiatric interview. Furthermore, documentation of exposure to smoking and assessment of outcome were performed by different study personnel. The duration of smoking prior to the onset of depression was unknown, precluding estimation of duration of exposure on depression. Inconsistencies in the number of cigarettes smoked per day may have resulted in misclassification of smoking frequency in the case–control analysis but the apparent dose-dependent association strengthens the notion that smoking is a risk factor for major depression. Small numbers limited a comparable investigation in the longitudinal analysis. Also in the longitudinal analysis, changes in exposure status during follow-up have not been identified. Finally, as in all observational studies, there may be unrecognised confounding. We relied on self-reported history of cardiovascular disease and diabetes as indicators of physical illness that may be affected by smoking status. However, we cannot exclude possible confounding by unrecognised comorbidity as individuals were not clinically screened for all potential physical illnesses. Physical activity and alcohol consumption were explored as concomitant lifestyle factors with a potential for confounding because physical activity had been previously reported as protective against depression, Reference Strawbridge, Deleger, Roberts and Kaplan31 whereas physical inactivity Reference Brown, Ford, Burton, Marshall and Dobson32Reference Farmer, Locke, Moscicki, Dannenberg, Larson and Radloff34 and alcohol misuse Reference Hamalainen, Kaprio, Isometsa, Heikkinen, Poikolainen, Lindeman and Aro6 are regarded as risk factors. In this study, alcohol consumption did not appear to confound the association between smoking and depression; however, we acknowledge that our criteria for alcohol consumption may have been too broad to confidently exclude its contribution. Other factors predisposing to depression, such as personality traits, developmental and family history of depression, IQ or stress, were not considered as these data were not available.

Within these limitations, however, our data corroborate literature that reveals a malevolent role of smoking in depression and suggest that greater efforts are required in targeting smoking as a routine intervention. Reference Berk35 Depression's status as a leading cause of global disease burden, Reference Murray and Lopez36,Reference Mathers, Vos, Stevenson and Begg37 one that is not anticipated to yield in the coming decades, Reference Murray and Lopez36 can only underscore the potential impact of any effective preventive measures.

Acknowledgements

The study was funded by the National Health and Medical Research Council of Australia, supported by an unrestricted educational grant from Eli Lilly. Postgraduate scholarships were provided by the University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences and the Australian Rotary Health Research Fund. We thank Sharon Brennan for obtaining the socio-economic data for the study.

Footnotes

Declaration of interest

J.P., L.W., F.J. and M.B. have received research support from an unrestricted educational grant from Eli Lilly. Funding detailed in Acknowledgements.

References

1 Grant, BF, Hasin, DS, Chou, SP, Stinson, FS, Dawson, DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004; 61: 1107–15.Google ScholarPubMed
2 Kilian, R, Becker, T, Kruger, K, Schmid, S, Frasch, K. Health behavior in psychiatric in-patients compared with a German general population sample. Acta Psychiatr Scand 2006; 114: 242–8.CrossRefGoogle ScholarPubMed
3 Dani, JA, De Biasi, M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001; 70: 439–46.CrossRefGoogle ScholarPubMed
4 Adan, A, Prat, G, Sanchez-Turet, M. Effects of nicotine dependence on diurnal variations of subjective activation and mood. Addiction 2004; 99: 1599–607.CrossRefGoogle Scholar
5 Harlow, BL, Cohen, LS, Otto, MW, Spiegelman, D, Cramer, DW. Prevalence and predictors of depressive symptoms in older premenopausal women: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 1999; 56: 418–24.CrossRefGoogle ScholarPubMed
6 Hamalainen, J, Kaprio, J, Isometsa, E, Heikkinen, M, Poikolainen, K, Lindeman, S, Aro, H. Cigarette smoking, alcohol intoxication and major depressive episode in a representative population sample. J Epidemiol Community Health 2001; 55: 573–6.CrossRefGoogle Scholar
7 Klungsoyr, O, Nygard, JF, Sorensen, T, Sandanger, I. Cigarette smoking and incidence of first depressive episode: an 11-year, population-based follow-up study. Am J Epidemiol 2006; 163: 421–32.CrossRefGoogle ScholarPubMed
8 Steuber, TL, Danner, F. Adolescent smoking and depression: which comes first? Addict Behav 2006; 31: 133–6.CrossRefGoogle ScholarPubMed
9 Henry, MJ, Pasco, JA, Nicholson, GC, Seeman, E, Kotowicz, MA. Prevalence of osteoporosis in Australian women: Geelong Osteoporosis Study. J Clin Densitom 2000; 3: 261–8.CrossRefGoogle ScholarPubMed
10 Adhikari, P. Socio-economic indexes for areas: introduction, use and plans for 2006. Presented at the Census Analysis Conference, 18–19 July 2006. Australian Bureau of Statistics.Google Scholar
11 First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for DSM–IV–TR Axis I Disorders, Research Version (Non-patient edn) (SCID–I/NP). Biometrics Research, New York State Psychiatric Institute, 2002.Google Scholar
12 Breslau, N, Kilbey, MM, Andreski, P. Nicotine dependence and major depression. New evidence from a prospective investigation. Arch Gen Psychiatry 1993; 50: 31–5.CrossRefGoogle ScholarPubMed
13 Breslau, N, Peterson, EL, Schultz, LR, Chilcoat, HD, Andreski, P. Major depression and stages of smoking. A longitudinal investigation. Arch Gen Psychiatry 1998; 55: 161–6.CrossRefGoogle ScholarPubMed
14 Brown, RA, Lewinsohn, PM, Seeley, JR, Wagner, EF. Cigarette smoking, major depression, and other psychiatric disorders among adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35: 1602–10.CrossRefGoogle ScholarPubMed
15 Malpass, D, Higgs, S. Acute psychomotor, subjective and physiological responses to smoking in depressed outpatient smokers and matched controls. Psychopharmacology (Berl) 2007; 190: 363–72.CrossRefGoogle ScholarPubMed
16 Kendler, KS, Neale, MC, MacLean, CJ, Heath, AC, Eaves, LJ, Kessler, RC. Smoking and major depression. A causal analysis. Arch Gen Psychiatry 1993; 50: 3643.CrossRefGoogle ScholarPubMed
17 Korhonen, T, Broms, U, Varjonen, J, Romanov, K, Koskenvuo, M, Kinnunen, T, Kaprio, J. Smoking behaviour as a predictor of depression among Finnish men and women: a prospective cohort study of adult twins. Psychol Med 2007; 37: 705–15.CrossRefGoogle ScholarPubMed
18 Foley, KF, DeSanty, KP, Kast, RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 2006; 6: 1249–65.CrossRefGoogle ScholarPubMed
19 Korf, J, van Praag, HM. Retarded depression and the dopamine metabolism. Psychopharmacologia 1971; 19: 199203.Google ScholarPubMed
20 Post, RM, Kotin, J, Goodwin, FK, Gordon, EK. Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness. Am J Psychiatry 1973; 130: 6772.CrossRefGoogle ScholarPubMed
21 Ebert, D, Feistel, H, Loew, T, Pirner, A. Dopamine and depression–striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl) 1996; 126: 91–4.CrossRefGoogle ScholarPubMed
22 Martinot, M, Bragulat, V, Artiges, E, Dolle, F, Hinnen, F, Jouvent, R, Martinot, J. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry 2001; 158: 314–6.CrossRefGoogle ScholarPubMed
23 Di Chiara, G, Bassareo, V. Reward system and addiction: what dopamine does and doesn't do. Curr Opin Pharmacol 2007; 7: 6976.CrossRefGoogle Scholar
24 Malhi, GS, Berk, M. Does dopamine dysfunction drive depression? Acta Psychiatr Scand Suppl 2007; 433: 116–24.Google Scholar
25 Hulea, SA, Olinescu, R, Nita, S, Crocnan, D, Kummerow, FA. Cigarette smoking causes biochemical changes in blood that are suggestive of oxidative stress: a case–control study. J Environ Pathol Toxicol Oncol 1995; 14: 173–80.Google ScholarPubMed
26 Ozguner, F, Koyu, A, Cesur, G. Active smoking causes oxidative stress and decreases blood melatonin levels. Toxicol Ind Health 2005; 21: 21–6.CrossRefGoogle ScholarPubMed
27 Ozcan, ME, Gulec, M, Ozerol, E, Polat, R, Akyol, O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004; 19: 8995.CrossRefGoogle ScholarPubMed
28 Bilici, M, Efe, H, Koroglu, MA, Uydu, HA, Bekaroglu, M, Deger, O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001; 64: 4351.CrossRefGoogle ScholarPubMed
29 Khanzode, SD, Dakhale, GN, Khanzode, SS, Saoji, A, Palasodkar, R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003; 8: 365–70.CrossRefGoogle ScholarPubMed
30 Yanik, M, Erel, O, Katoi, M. The relationship between potency of oxidative stress and severity of depression. Acta Neuropsychiatrica 2004; 16: 200–3.CrossRefGoogle ScholarPubMed
31 Strawbridge, WJ, Deleger, S, Roberts, RE, Kaplan, GA. Physical activity reduces the risk of subsequent depression for older adults. Am J Epidemiol 2002; 156: 328–34.CrossRefGoogle ScholarPubMed
32 Brown, WJ, Ford, JH, Burton, NW, Marshall, AL, Dobson, AJ. Prospective study of physical activity and depressive symptoms in middle-aged women. Am J Prev Med 2005; 29: 265–72.CrossRefGoogle ScholarPubMed
33 Camacho, TC, Roberts, RE, Lazarus, NB, Kaplan, GA, Cohen, RD. Physical activity and depression: evidence from the Alameda County Study. Am J Epidemiol 1991; 134: 220–31.CrossRefGoogle ScholarPubMed
34 Farmer, ME, Locke, BZ, Moscicki, EK, Dannenberg, AL, Larson, DB, Radloff, LS. Physical activity and depressive symptoms: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1988; 128: 1340–51.CrossRefGoogle ScholarPubMed
35 Berk, M. Should we be targeting smoking as an intervention? Acta Neuropsychiatrica 2007; 19: 131–2.Google Scholar
36 Murray, CJ, Lopez, AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–504.CrossRefGoogle ScholarPubMed
37 Mathers, CD, Vos, ET, Stevenson, CE, Begg, SJ. The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factors. Med J Aust 2000; 172: 592–6.Google ScholarPubMed
Figure 0

Table 1 Participant characteristics in the case–control studySmoking frequency (number of cigarettes per day) and the risk for major depressiona

Figure 1

Table 2 Smoking frequency (number of cigarettes per day) and the risk for major depressiona

Figure 2

Fig. 1 Independent contributions of tobacco smoking and physical activity to the risk for major depression. Non-smokers who are physically active form the reference group.

Figure 3

Table 3 Participant characteristics in the retrospective cohort study

Figure 4

Fig. 2 Survival plot (Kaplan–Meier) showing the probability of remaining free of de novo major depressive disorder over a 10-year period for smokers and non-smokers at baseline.

Submit a response

eLetters

No eLetters have been published for this article.
You have Access
155
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Tobacco smoking as a risk factor for major depressive disorder: population-based study
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Tobacco smoking as a risk factor for major depressive disorder: population-based study
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Tobacco smoking as a risk factor for major depressive disorder: population-based study
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *